This study retrospectively analysed the clinical profile, treatment approaches, and outcomes of patients diagnosed with pancreatic and periampullary carcinomas at a tertiary cancer centre. The patient demographics showed a predominance of older adults and males. Common presenting symptoms being abdominal pain and jaundice, with a significant proportion reporting weight loss. Elevated CA 19-9 levels were observed, indicating advanced disease. The TNM staging showed a high incidence of late-stage disease at diagnosis. Various treatment modalities were employed, reflecting the complexity and personalised nature of the disease management. The analysis of survival outcomes, based on the Kaplan-Meier method, revealed significant disparities, underlining the importance of age as a prognostic factor. The study findings underscore the necessity for a comprehensive, multidisciplinary, and personalised approach to managing pancreatic and periampullary carcinomas. They provide a foundation for future research to refine detection strategies and treatment protocols and enhance patient outcomes. .

Keywords: Pancreatic Carcinoma; Periampullary Carcinoma; Treatment Modalities; Disease Outcomes; Prognostic Factors

References

1. Kimura W and Ohtsubo K. “Incidence, sites of origin, and immunohistochemical and histochemical characteristics of atypical epithelium and minute carcinoma of the papilla of Water”. Cancer 61 (1988): 1394-1402.
2. Panzeri F., et al. “Management of ampullary neoplasms: A tailored approach between endoscopy and surgery”. World Journal of Gastroenterology 21 (2015): 7970-7987.
3. Albores-Saavedra J., et al. “Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program”. Journal of Surgical Oncology 100 (2009): 598-605.
4. Herman J M., et al. “Ampulla of vater”. In: Amin M. B., editor. AJCC Cancer Staging Manual. 8^th. Chicago, USA: AJCC (2015): 2017327.
5. Rattner DW., et al. “Defining the criteria for local resection of ampullary neoplasms”. JAMA Surgery 131 (1996): 366-371.
6. Zhou Y., et al. “The histopathologic type predicts survival of patients with ampullary carcinoma after resection: a meta-analysis”. Pancreatology 17 (2017): 273-278.
7. Reid MD., et al. “Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases”. Modern Pathology 29 (2016): 1575-1585.
8. Eckel F and Jelic S. “Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up”. Annals of Oncology 20 (2009): 46-48.
9. Zhao X., et al. “Prognostic factors for survival of patients with ampullary carcinoma after local resection”. ANZ Journal of Surgery 85 (2015): 567-571.
10. Talamini M A., et al. “Adenocarcinoma of the ampulla of vater. A 28-year experience”. Annals of Surgery 225 (1997): 590-599.
11. Winter J M., et al. “Clinicopathologic analysis of ampullary neoplasms in 450 patients: Implications for surgical strategy and long-term prognosis”. Journal of Gastrointestinal Surgery 14 (2010): 379-387.
12. Cloyd JM., et al. “Influence of preoperative therapy on short- and long-term outcomes of patients with adenocarcinoma of the ampulla of vater”. Annals of Surgical Oncology 24 (2017): 2031-2039.
13. Narang AK., et al. “Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study”. Journal of Radiation Oncology 6 (2011): 126.
14. O'Connell J., et al. “Survival after resection of ampullary carcinoma: a national population-based study”. Annals of Surgical Oncology 15 (2008): 1820-1827.
15. Katz M H., et al. “Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques”. Journal of the American College of Surgeons 215 (2012): 11-18.
16. Neoptolemos J., et al. “Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial”. Journal of the American Medical Association 308 (2012): 147-156.
17. Bhatia S., et al. “Adjuvant therapy for ampullary carcinomas: The Mayo Clinic experience”. International Journal of Radiation Oncology, Biology, Physics 66 (2006): 514-519.
18. Klinkenbijl JH., et al. “Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group”. Annals of Surgery 230 (1999): 776-784.
19. Sikora S., et al. “Adjuvant chemo-radiotherapy in ampullary cancers”. European Journal 158 (2015): 163.
20. Kwon J., et al. “Survival benefit of adjuvant chemoradiotherapy in patients with ampulla of vater cancer”. Annals of Surgery 262 (2015): 47-52.
21. Lee JH., et al. “Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas”. International Journal of Radiation Oncology, Biology, Physics 47 (2000): 945-953.
22. Kamarajah SK. “Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis”. Clinical and Translational Oncology 20 (2018): 12121218.
23. Chavez M., et al. “Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma”. The American Journal of Surgery 214 (2017): 856-861.
24. Smith J., et al. “Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas”. Biomolecules 25 (2021): 1766.
25. Conroy T., et al. “Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer”. The New England Journal of Medicine 12 (2011): 1817-1825.
26. Pannala R., et al. “New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer”. Lancet Oncology 10 (2009): 88-95.
27. Wang Y., et al. “Single-Cell Transcriptomics of the Human Endocrine Pancreas”. Diabetes 65 (2016): 3028-3038.
28. Arda H., et al. “A Chromatin Basis for Cell Lineage and Disease Risk in the Human Pancreas”. Cell System 26 (2018): 310-322.
29. Vincent A., et al. “Pancreatic cancer”. Lancet 13 (2011): 607-620.
30. Ducreux M., et al. “ESMO Guidelines Committee: Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Annals of Oncology 26 (2015): 56-68.

Citation

Citation: Ruchir Tandon., et al. “Clinical Profile, Treatment and Outcomes of Patients with Pancreatic and Periampullary Carcinoma from a Tertiary Cancer Centre: A Retrospective Study”.Acta Scientific Cancer Biology 7.10 (2023): 32-41.

Copyright

Copyright: © 2023 Ruchir Tandon., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.